{"name":"Pieris Pharmaceuticals","slug":"pieris","ticker":"PIRS","exchange":"NASDAQ","domain":"pieris.com","description":"Anticalin proteins are artificial proteins that are able to bind to antigens, either to proteins or to small molecules. They are not structurally related to antibodies, which makes them a type of antibody mimetic. Instead, they are derived from human lipocalins which are a family of naturally binding proteins. Anticalin proteins are being used in lieu of monoclonal antibodies, but are about eight times smaller with a size of about 180 amino acids and a mass of about 20 kDa.","hq":"Boston, MA","founded":0,"employees":"","ceo":"Stephen Yoder","sector":"Biopharmaceuticals / Protein Engineering","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$55M","metrics":{"revenue":42810000,"revenueGrowth":65.3,"grossMargin":0,"rdSpend":8151000,"netIncome":-17434000,"cash":88234000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"PRS-343 patent cliff ($0.0B at risk)","drug":"PRS-343","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"PRS-344 patent cliff ($0.0B at risk)","drug":"PRS-344","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Pieris Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Pieris Pharmaceuticals reported its fourth quarter and full year 2023 financial results, highlighting progress in its pipeline and commercial operations.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"Pieris Pharmaceuticals Announces Collaboration with Merck to Develop Novel Cancer Therapies","summary":"Pieris Pharmaceuticals entered into a collaboration with Merck to develop novel cancer therapies using Pieris' proprietary Anticalin technology.","drugName":"","sentiment":"positive"},{"date":"2023-08-28","type":"trial","headline":"Pieris Pharmaceuticals Announces Positive Topline Results from Phase 1 Clinical Trial of PRS-343","summary":"Pieris Pharmaceuticals announced positive topline results from a Phase 1 clinical trial of PRS-343, a novel cancer therapy.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPeVN6S0tOd29HcS04WFBTZGk4azBSN3E5OC1Qa3V5VUo3emk2S0J5ZWt0YmtLZkdyQUpHNnVNaVZ1VnNKTHUtUHdYVFF5ckJZQ3F2bGdQb21CSVNXekdrTlY1bUhrR2NKVHYzcWFaZlAxcm1xUEMyWDcxYUI5dzExVmloa0dnUk9qd2Y4bUstQkhiOHBzSFpscUNna3BXV0NzOWRvV24wOHF1T0ZURTlId1pocWh2cHdsR0Nv?oc=5","date":"2026-02-17","type":"pipeline","source":"AD HOC NEWS","summary":"Pieris Pharmaceuticals: What a Delisting Biotech Still Signals for Risk?Hungry Traders - AD HOC NEWS","headline":"Pieris Pharmaceuticals: What a Delisting Biotech Still Signals for Risk?Hungry Traders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNbXFhRXVJN1l2elptcnVVemxqbHM2cm9fUUJXaDRxN0ViQnNqaWQ4NldSOEtNSTFNdV9qTHNfZVhVQ1cxMkdhTDBWeVREVmJycW54d3JOeTFvaGFER1hlOUhpVUhRd09FRlpRQ3ZBWmJNbTJmU3JOMjZ2YVNDS0dqWUJDMzhKcjQ5TTdCbGFNZjBJSzk3NjYyRGs4dFpvUWc5T21acFFzbWEzZw?oc=5","date":"2024-11-14","type":"pipeline","source":"BioSpace","summary":"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer - BioSpace","headline":"Greywolf Appoints Darlene Deptula-Hicks as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQYl9yT3U1cGFNaE5zN0taSUdxUEx5V19MWEVIUE5nWmZ6SGtGS05VQjRlV2JqeFp6akdrSUhsdjE3eVJWeTRkZlJxZlc3QTFyM3BDeFhHVzdlWW1hVmRndTlaVXF5a09YWkl5dlFhMm14QWFsbUFwMi05V014TWJuaVlpSWNDaUZzVV9ScHltTzJlWmJKeWdTN2xGNEFFcWlvd1ROMEFxV0k3RmJWUzVwcjZB?oc=5","date":"2024-08-15","type":"deal","source":"The Business Journals","summary":"Inside the deal: How Palvella Therapeutics plans to go public through a reverse merger with a Boston pharma firm - The Business Journals","headline":"Inside the deal: How Palvella Therapeutics plans to go public through a reverse merger with a Boston pharma firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQU0Fqd1hhY0tnNGxqekZRSkRVcFlnNnllVEY0UEtjTVV1Y05uRk1pQVFybm1NNVJzU3dfaTNHTTJpSDRFSzlyUVZrbjVJZWRDNDNUSnQyVEktZE5ZeXV5QkRzdXBSX251VExpQW90Q0RkR3ZCMXhoY1FPTWU3YVdjSHNWYTY2WnhwQUR4N05JQVUxQk03Zm9RUXZUY1dRYkIy?oc=5","date":"2024-07-24","type":"deal","source":"Yahoo Finance","summary":"Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement - Yahoo Finance","headline":"Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNc3BHX3BuOWFyQWdoRlZWTTQ2N1ZJOUxfSHRLb2RUOVFjVm1BWW9fUU1TSENRVjNwT0Via2VXZGJUZ2ZwLVo5Q3VHcEgxQm5ia043ZV9CM3gwaHJ0ODh3SDVSSzZIa3R2YUtpOEZuRUVMZmZCNy1WMXdTQXJ0VnBXbjF4U0R6d1poS1gtMHo0dlEzTHpreDYw?oc=5","date":"2024-04-25","type":"pipeline","source":"intelligentinvestor.com.au","summary":"Pieris Pharmaceuticals (NASDAQ: PIRS) - Share Price - intelligentinvestor.com.au","headline":"Pieris Pharmaceuticals (NASDAQ: PIRS) - Share Price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBJR1A0V3FZQUoyZGhkcEVnelpVMk9iVGZGZXljLWdSUU9HVEdjZ2VRTDVZYnhpbkhEN0VPN1NVSm9XS005eWd4SzB6czFWNnFMaTZhbDh5aXVOdGFON3M3VXV6UU5yaUh3ZEstN1ZwcGpxZXZmM1ZLaVdXRFY1dw?oc=5","date":"2021-10-14","type":"pipeline","source":"The Motley Fool","summary":"2 Penny Stocks That Could Soar Soon - The Motley Fool","headline":"2 Penny Stocks That Could Soar Soon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBaeW1KV1pWR1p6cWRTeEJyeHJUZlJxT3FwTEYyaGpNY0ktRnl4MHhFWjNPSF9qZXBTaG5DMFJnOWtqRDUydXVxNkRJbzVJaGZI?oc=5","date":"2021-09-13","type":"pipeline","source":"The Motley Fool","summary":"Pieris Pharmaceuticals - PIRS - Stock Price & News - The Motley Fool","headline":"Pieris Pharmaceuticals - PIRS - Stock Price & News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxNYXplelljeTViTTMzVFU5MjlQM2ppTFlVbHFpa2ZFMnp0VGZhZGgydjlnbDgzc3dFUjd3akMyQjhPS1Vwdkh1M0FmazBrNkRMRVRoeGZiZ2sxTUZfTzJaQnhUR0x4SHFlaFJPNmIyX2s0d0JmRlNvaVFkNi0wNGwzXzZEcWtxUkFTcnowbVBKeHdOOTNwNWsxUzUwQ3Q3RDd0YXY0U0xhS0lLM09BUEFpM24wYklqLVRuTFY2V3VBSVBpUDBkWXhOdHFOYUhQVmpPNUFZSG5fbzhwYVdZOEpmOTJXWXczRlQ0bXNxbVZpV1RSM2ZBdGlQTlRlZkhtMWVhbHIxUGlwZEZMTnVWNDhfNkFlQi1hbjVSX1Y0eVl1cWVUcmxQN1owZVNUQU1iMm5R?oc=5","date":"2021-04-26","type":"deal","source":"Business Wire","summary":"Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - Business Wire","headline":"Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB","sentiment":"neutral"}],"patents":[{"drugName":"PRS-343","drugSlug":"prs-343","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"PRS-344","drugSlug":"prs-344","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Gilead Sciences","Regeneron Pharmaceuticals"],"therapeuticFocus":["Oncology","Respiratory Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":42810000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":42810000,"period":"2023-12-31"},{"value":25902000,"period":"2022-12-31"},{"value":25902000,"period":"2022-12-31"},{"value":31418000,"period":"2021-12-31"},{"value":31418000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":8151000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-17434000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":88234000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}